Colorectal Cancer Metastatic Clinical Trial
— MODULATEOfficial title:
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
Verified date | August 2021 |
Source | Australasian Gastro-Intestinal Trials Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This Phase II research project will test the efficacy, safety, and tolerability of an experimental drug combination: either nivolumab and BBI608 or nivolumab and BNC105 in patients with metastatic colorectal cancer who have previously failed standard of care treatment.
Status | Completed |
Enrollment | 90 |
Est. completion date | April 9, 2021 |
Est. primary completion date | January 29, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patient has a histological diagnosis of adenocarcinoma of colorectal origin. 2. Has documented microsatellite stable tumour as assessed by PCR or IHC. 3. Metastatic disease that is not resectable. 4. Male or female patients > 18 years of age at screening. 5. Failed in any sequence or combination oxaliplatin, fluoropyrimidine, irinotecan with or without bevacizumab where failure is defined as progression or toxicity precluding further therapy. 6. For patients with ras/b-raf wild type tumours: failed anti EGFR therapy (cetuximab and/or panitumumab) where failure is defined as progression or toxicity precluding further therapy. Patients with b-raf mutant tumours and/or right sided primary tumours may have received anti-EGFR therapy but this is not mandated. 7. Patient has measurable disease according to RECIST 1.1. 8. Metastatic lesion(s) amenable to biopsy, this cannot be the sole site of measurable disease. 9. ECOG performance status 0 or 1. 10. Adequate organ and hematologic function within 7 days of randomisation, defined by: 1. Neutrophils > 1.5 X 109/L 2. Platelets > 80 X 109/L 3. Serum aspartate transaminase (AST) or alanine transaminase (ALT) < 3 x upper limit of normal (ULN) 4. Bilirubin < 1.5 x ULN 5. Albumin >30g/L 6. Creatinine clearance = 50ml/min(Cockcroft-Gault). 11. Life expectancy of at least 12 weeks 12. No other concurrent uncontrolled medical conditions 13. No other malignant disease apart from non-melanotic skin cancer or carcinoma in situ of the uterine cervix or any other cancer treated with curative intent >2 years previously without evidence of relapse. 14. Female patients of childbearing potential should have a negative urine or serum pregnancy within 24 hours prior to randomisation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required 15. Female patients of childbearing potential should be willing to use a reliable method of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 180 days after the last dose of study medication. Patients of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year. 16. Male patients with female partners of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy. 17. Patient has provided written informed consent including consent for tumour biopsies and donation of tumour tissue for biomarker studies. Exclusion Criteria: 1. Medical or psychiatric conditions that compromise the patient's ability to give informed consent or to complete the protocol. 2. Patients with any active, known, or suspected autoimmune disease, with the following exceptions: 1. Patients with vitiligo, type 1 diabetes mellitus, resolved childhood asthma or atopy are permitted to enroll. 2. Patients with suspected autoimmune thyroid disorders may be enrolled if they are currently euthyroid or with residual hypothyroidism requiring only hormone replacement. 3. Patients with psoriasis requiring systemic therapy must be excluded from enrolment 3. Patients with a condition requiring systemic treatment with either corticosteroids (>10 mg/day prednisone equivalent) or other immunosuppressive medications within 14 days of randomisation. Inhaled or topical steroids and adrenal replacement doses > 10mg/day prednisone equivalents are permitted in the absence of active autoimmune disease. 4. Patient has evidence of interstitial lung disease or active, non-infectious pneumonitis. 5. Has an active infection requiring systemic therapy. 6. Patients receiving long-term anti-coagulation or anti-platelet agents which cannot be ceased for an appropriate interval to allow mandatory tumour biopsies prior to and during therapy. 7. Patient has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate. 8. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways). 9. Has a known history of HIV (HIV 1/2 antibodies). Formal testing is only required if there is significant clinical suspicion of HIV. 10. Known active brain metastases (unless adequately treated with surgery and/or radiotherapy >30 d prior and asymptomatic). 11. Significant vascular events within the previous 6 months (unstable angina, myocardial infarction, TIA, CVA). |
Country | Name | City | State |
---|---|---|---|
Australia | Border Cancer Hospital | Albury | New South Wales |
Australia | Ballarat Health Service | Ballarat | Victoria |
Australia | Flinders Medical Centre | Bedford Park | South Australia |
Australia | Eastern Health | Box Hill | Victoria |
Australia | Monash Health | Clayton | Victoria |
Australia | Olivia Newton-John Cancer Wellness and Research Centre | Heidelberg | Victoria |
Australia | Royal Brisbane Hospital | Herston | Queensland |
Australia | Ashford Cancer Centre Research | Kurralta Park | South Australia |
Australia | Peninsula Health/Frankston Hospital | Mornington Peninsula | Victoria |
Australia | Newcastle Private Hospital | Newcastle | New South Wales |
Australia | Western Health | Saint Albans | Victoria |
Australia | Northern Cancer Institute | St Leonards | New South Wales |
Australia | Westmead Hospital | Westmead | New South Wales |
Australia | Queen Elizabeth Hospital | Woodville South | South Australia |
Lead Sponsor | Collaborator |
---|---|
Australasian Gastro-Intestinal Trials Group |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective response per iRECIST | From start of treatment up to the date when the last patient has their 6 months follow-up assessment | ||
Secondary | Objective response per RECIST1.1 | From start of treatment up to the date when the last patient has their 6 months follow-up assessment | ||
Secondary | Progression free survival (PFS). | From start of treatment until the date of first documented progression or date of death from any cause, whichever occurs first, assessed up to the date when the last patient has their 6 months follow-up assessment | ||
Secondary | Adverse event assessed using CTCAE version 5.0 | Through treatment completion, maximum of 2 years | ||
Secondary | Overall survival | From start of treatment until the date of death from any cause, assessed up to the date when the last patient has their 6 months follow-up assessment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03941080 -
Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer
|
||
Completed |
NCT03213314 -
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
|
N/A | |
Recruiting |
NCT05057052 -
Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis
|
Phase 2 | |
Terminated |
NCT02316496 -
Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study
|
Phase 2 | |
Completed |
NCT03251612 -
Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT02380443 -
AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT02149784 -
Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients
|
Phase 3 | |
Recruiting |
NCT01959061 -
Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases
|
Phase 4 | |
Terminated |
NCT01668680 -
Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma
|
Phase 2 | |
Recruiting |
NCT05068531 -
Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
|
||
Not yet recruiting |
NCT04525807 -
Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
|
||
Completed |
NCT04482608 -
The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
|
||
Recruiting |
NCT03193710 -
The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved
|
N/A | |
Recruiting |
NCT04854213 -
PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)
|
N/A | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03144804 -
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT03142516 -
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
|
Phase 2 | |
Active, not recruiting |
NCT01910610 -
Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer
|
Phase 3 | |
Recruiting |
NCT05759728 -
A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04874207 -
Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib
|
Phase 4 |